Interface makes two new appointments
This article was originally published in Scrip
Executive Summary
Interface Biologics, a Canadian developer of biomedical polymers, has appointed Thomas Reeves president, CEO and member of the board, and Lily Lam as a member of the board, in connection with the company's recently secured $5 million financing round. Mr Reeves was most recently president and chief operating officer of OccuLogix, a medical device company, whilst Ms Lam is a vice- president of investments at Covington Capital.